Spago takes Tumorad-01 study to the next level

Spago Nanomedical has increased the dose of its cancer drug candidate 177Lu-SN201 in its phase I/IIa Tumorad-01 study, following a recommendation from the independent Data Monitoring Committee.

The decision stems from data on six patients across two cohorts with five different cancer types, all showing a satisfactory safety profile.